CA-NETAPP
16.3.2021 15:02:14 CET | Business Wire | Press release
Less than a year after joining global software leader NetApp (NASDAQ: NTAP) as its President, César Cernuda has announced changes to the go-to-market (GTM) model and global sales organization that will help steer the company into its cloud-led future.
Cernuda is instituting a customer- and partner-centric strategic and operational evolution that will allow NetApp to move to a customer engagement model focused on driving deeper specialization and delivering hybrid cloud expertise powered by digitization. The changes will see the company ramp up its efforts to drive consistency and simplicity across its global sales organization and more aggressively address key markets and segments while reaching new customers and partners.
“With today’s relentless pace of change, speed is the new scale. And that’s what organizations are demanding as they try to put their data to work to keep innovating and stay ahead of the digital curve,” said César Cernuda. “We are implementing these changes to better serve their needs. We will soon deliver a personalized, data-driven engagement model that allows our current and future customers to move at warp speed and aligns with the new way they want to engage with their solution partners.”
The evolution of NetApp’s sales organization will also result in changes and additions to the sales leadership team, effective May 1, 2021:
- NetApp veteran and former SVP, Globals, Verticals, and Pathways, Rick Scurfield will serve in the company’s newly established role of Chief Commercial Officer . Scurfield will be responsible for building a new GTM motion and strategy including direct sales and channel coverage and will drive the transformation of NetApp’s digital and virtual sales teams and Sales Operations to better enable NetApp’s sales force and worldwide partnerships. Scurfield has led winning sales organizations for more than 20 years, most recently growing and leading sales teams supporting NetApp’s largest global accounts, vertical segments, global pathways, and the U.S. Public Sector.
- Max Long , former SVP, Chief Customer Officer at Adobe, will be joining NetApp as the company’s new SVP, North America . Leveraging his 30+ years of experience building high-performance sales teams and leading business transformations. Long will continue the focus on aligning NetApp’s business objectives in the U.S. and Canada driven by our customer’s business requirements. He will lead direct sales, channel sales, and demand generation teams.
- Alex Wallner, also a NetApp veteran who most recently served as SVP, Worldwide Enterprise and Commercial Field Operations, will take on the newly created role of SVP, International . Wallner will lead the execution of all GTM activities for the EMEA, APAC and Latin America regions. Focusing on increasing the footprint of NetApp as the partner-of-choice for our international customers, he and his team will help customers address their data challenges with hybrid multi-cloud solutions including NetApp’s data center architectures and superior cloud software portfolio.
“Rick’s and Alex’s proven leadership and in-depth knowledge of our industry, our customers and our partners combined with Max’s track record of leading enterprise sales teams to success at scale will be instrumental in helping organizations everywhere unlock the best of today’s hybrid multi-cloud world, wherever they are on their digital transformation journey—on premises or in any cloud,” added Cernuda.
The evolution of the NetApp data-driven GTM model and cloud-led sales organization is expected to be a continuous process starting in Q1 FY22.
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005711/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom